Atara Biotherapeutics (ATRA) vs Cardiff Oncology (CRDF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Cardiff Oncology (CRDF) over the past year, losing 41.0% versus a loss of 54.6%. Over five years, CRDF leads with a -83.1% price change compared with -97.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($95.2 million vs $84.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | CRDF |
|---|---|---|
| Share price | $9.48 | $1.08 |
| Market cap | $95.16M | $84.02M |
| 1-day change | +2.71% | +1.89% |
| YTD return | -47.60% | -61.57% |
| 1-year return | -41.04% | -54.62% |
| 5-year return | -97.56% | -83.13% |
| Forward P/E | 6.14 | — |
| EPS (TTM) | $-1.30 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $3.31 |
| 52-week low | $3.92 | $0.76 |
| Distance from 52-week high | -50.48% | -67.37% |
| Analyst consensus | buy | none |
| Avg. price target upside | +44.20% | +437.96% |
| Average volume | 53.58K | 1.05M |
| Shares outstanding | 10.04M | 77.80M |
| Employees | 10 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed CRDF by 13.6 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
ATRA vs CRDF FAQ
Which is bigger, Atara Biotherapeutics or Cardiff Oncology?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $95.16M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, ATRA or CRDF?
ATRA returned -41.04% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Cardiff Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.